Results 201 to 210 of about 133,285 (252)

Glutaraldehyde in whole-cell Bordetella pertussis vaccine

Vaccine, 1989
Treatment of the whole-cell bacterial suspensions of Bordetella pertussis with 0.05% glutaraldehyde at room temperature for 10 min kills the bacteria and, except for some histamine sensitising activity, almost detoxifies the pertussis toxin. The glutaraldehyde-vaccine is of good potency with a meritorious performance in tests for abnormal toxicity in ...
S C, Arya, S J, Ashraf, V P, Pathak
openaire   +2 more sources

Whole-Cell Vaccine Preparation: Options and Perspectives

2020
Vaccines are biological preparations to elicit a specific immune response in individuals against the targetted microorganisms. The use of vaccines has caused the near eradication of many critical diseases and has had an everlasting impact on public health at a relatively low cost.
Punit, Kumar, , Sunita, Kashyap Kumar, Dubey, Pratyoosh, Shukla   +3 more
openaire   +2 more sources

Development of a whole cell vaccine for acute myeloid leukaemia

Cancer Immunology, Immunotherapy, 2005
We describe the modification of tumour cells to enhance their capacity to act as antigen presenting cells with particular focus on the use of costimulatory molecules to do so. We have been involved in the genetic modification of tumour cells to prepare a whole cell vaccine for nearly a decade and we have a particular interest in acute myeloid leukaemia
Cheuk, Adam T.C., Chan, Lucas, Czepulkowski, Barbara, Berger, Stuart A., Yagita, Hideo, Okumura, Ko, Farzaneh, Farzin, Mufti, Ghulam J., Guinn, Barbara-ann   +8 more
openaire   +3 more sources

Differences in Antibody Response to Whole-Cell Pertussis Vaccines

Pediatrics, 1991
It has been assumed that whole-cell pertussis vaccines (WCVs) commercially distributed in the United States are of comparable immunogenicity, as all must comply with established standards for licensure. However, we have recently noted significant differences in antibody responses between groups of infants receiving the two WCVs commercially available ...
K M, Edwards, M D, Decker, N A, Halsey, B A, Koblin, T, Townsend, B, Auerbach, D T, Karzon   +6 more
openaire   +2 more sources

Pertussis vaccines: acellular versus whole‐cell

Medical Journal of Australia, 1996
Acellular pertussis vaccines containing purified Bordetella pertussis antigens have now been extensively field tested. They produce a significantly lower rate of reactions than whole-cell vaccines and their efficacy is either comparable or superior.
openaire   +2 more sources

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

Journal of Applied Microbiology, 2018
Pneumococcal infections are a major public health problem, especially in developing countries, and the current pneumococcal vaccines do not cover all pathogenic strains. New, more economical serotype-independent vaccines based on species-common protein antigens are being pursued.
M. Mohammadzadeh, B. Pourakbari, A. Doosti, S. Mahmoudi, M. Habibi-Anbouhi, S. Mamishi   +5 more
openaire   +2 more sources

Induction of T Cell Responses by Vaccination of a Streptococcus pneumoniae Whole-Cell Vaccine

2021
The induction of T cell responses by vaccination is important for protection against infection. We have previously shown that immunization with a killed Streptococcus pneumoniae whole-cell vaccine (SPWCV) by either intranasal immunization or subcutaneous immunization induced T cell responses to SPWCV. Protection against colonization by S. pneumoniae is
Emily M, Roy, Fan, Zhang, Richard, Malley, Ying-Jie, Lu   +3 more
openaire   +2 more sources

Priming with Whole-Cell versus Acellular Pertussis Vaccine

New England Journal of Medicine, 2013
About 15 years ago, as part of the pediatric series of vaccines for diphtheria, tetanus, and pertussis, a transition from whole-cell to acellular pertussis vaccine occurred.
Juventila, Liko, Steve G, Robison, Paul R, Cieslak   +2 more
openaire   +2 more sources

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine

The Journal of Pediatrics, 1994
The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine.
PODDA A, DELUCA EC, CONTU B, FURLAN R, MAIDA A, MOIRAGHI A, STRAMARE D, TITONE L, UXA F, DIPISA F, PEPPOLONI S, NENCIONI L, RAPPUOLI R, BARTALINI M, BONA, Gianni, BUDRONI M, PISTILLI AMC, CASCIO A, CASCIO G, COSSU M, DALLORTO P, DILEO G, FURLAN A, MACAGNO F, MARSILI I, MELONI T, REGOLI D, RIGO G, TRAPPAN A, VARGIU G, VOLPINI G.   +30 more
openaire   +2 more sources

Chitosan-Deficient Cryptococcus as Whole-Cell Vaccines

Creating a safe and effective vaccine against infection by the fungal pathogen Cryptococcus neoformans is an appealing option that complements the discovery of new small molecule antifungals. Recent animal studies have yielded promising results for a variety of vaccines that include live-attenuated and heat-killed whole-cell vaccines, as well as ...
Charles A, Specht, Woei C, Lam, Maureen M, Hester, Diana, Lourenco, Stuart M, Levitz, Jennifer K, Lodge, Rajendra, Upadhya   +6 more
openaire   +2 more sources